Express Search Internal
Express Search, Inc
8001 Braddock Road
Suite 330
Springfield, VA 22151


To access the full version of these results, including the searchable PDF versions of f the references, please email Projects@ExpressSearch.com or call 703.535.5455
Re:
Patent Landscape Search
Biotech Landscape
Sample for Website
 

July 01, 2018

Dear Mr. Search,

In accordance with your e-mail received on April 19, 2018 , a Patent Landscape Search was conducted for a biotech landscape search, in accordance with the disclosure provided.

 

OUR PATENT LANDSCAPING DELIVERS KNOWLEDGE YOU CAN ACT ON

Express Search has offered high quality, value-driven patent landscaping research in broad technology areas for over 20 years. Despite the changing nature and increasing importance of patent landscaping art, our lengthy tenure in patent research and proprietary analytics technology attest to our success in delivering actionable and high quality analysis to industry, academia, government and entrepreneurs.

Instead of providing a huge stack of patent documents to be reviewed or requiring clients to learn complicated analytic programs to obtain results, we focus individual attention to each case and to client sector- from key decision makers, R&D and patent law departments.

Our expert researchers will help you devise and optimize your search strategy, visualize your results from many angles, and provide support throughout the process to deliver timely, cost-effective, easily updated, and actionable results for strategic and tactical decision making.

The patent landscape presented below demonstrates the advantages of using Express Search to obtain a complete and valuable perspective on potential biological therapies in neurodegenerative disorders- one of the most challenging diseases that affect the population with extreme medical and financial burdens.

EXECUTIVE SUMMARY

EXECUTIVE SUMMARY

FOCUS OF REVIEW

This patent landscape focuses on potential biological drug targets and therapies for neurodegenerative diseases, and in particular on patent documents disclosing genetic and molecular insights to target new prospects and strategies for potential drug target discovery in this challenging area. Patent documents relating to small chemical entities have been excluded due to their limited success and failure in clinical trials. For example, a 2014 study reported that 99% of new Alzheimer’s drugs in 413 trials failed between 2002 and 2012. In addition, these chemical entities only target symptoms of the disease, but none target the underlying cause.

Our rationale for focusing on biological drug targets and therapies for neurodegenerative diseases is based the surge of investor enthusiasm in new generation of neuroscience-focused biotech companies poised to change the paradigm of drug discovery in this largely impenetrable area. Armed with genetic insights, therapeutic technologies, and diagnostic tools, biotech researchers think the brain can be coaxed into giving up its secrets. These biotech companies have ignited investor enthusiasm for funding drug discovery in this notoriously difficult area. According to a recent review by the Biotechnology Innovation Organization, venture capital investment in neurology-focused start-ups more than doubled in 2012-16 compared to the prior five years, to more than $2 billion. This venture activity occurred during a period when the majority of large Pharma reduced their internal efforts or backed out completely.

NEURODEGENERATIVE DISEASES

The term “Neurodegenerative Diseases” (NDDs) identifies a heterogeneous group of disorders characterized by progressive degeneration of the structure and function of the central or peripheral nervous systems. All neurodegenerative diseases, whatever their etiology, converge on a single event: the death of neurons. The evidence of common features involved in neuronal death is represented by intracellular accumulation and aggregation of misfolded proteins, abnormal cellular transport and mitochondrial deficits. . Quite recently, inflammation has been confirmed as another essential contributing factor, in which reactive astroglia and/or microglia seem to play key roles.

Many neurodegenerative diseases - including Alzheimer’s, Parkinson’s, Huntington’s, and Amyotrophic Lateral Sclerosis (ALS) are becoming increasingly prevalent due to an aging population, and have a devastating human cost on the lives of patients and families, as well as a burden on healthcare systems and society. For example, the cost to society of Alzheimer’s disease is estimated to skyrocket to $1 trillion annually in the U.S. by the year 2050. Because neurodegenerative diseases strike primarily in mid-to-late life, the incidence is expected to soar as the population ages. (By 2030, as many as 1 in 5 Americans will be over the age of 65.) If left unchecked 30 years from now, more than 12 million Americans will suffer from neurodegenerative diseases. Finding treatments and cures for neurodegenerative diseases is a goal of increasing urgency.

SCOPE

The scope of this patent landscape is to detect patterns of patenting activity and innovation for biotherapeutic neurodegenerative disease drug inventions generated from emerging molecular mechanisms and genetic information.Patent documents included in the landscape claim inventions related to RNA biology, nuclear transport, protein aggregation, protein processing, axonal protection, synaptic resilience, more effective antibody technologies, boosting the immune system with vaccines, disease-modifying antisense oligonucleotides, and gene therapy.  With the advancement of biologic technologies, there is promise for these therapeutics as novel therapeutic approaches for neurological diseases.

Patent activity over the past decade demonstrates the identification of new mutation mechanisms, such as triplet repeat expansions, and new genes causing familial forms of common neurodegenerative diseases, such as Parkinson’s and Alzheimer’s diseases. Cellular and animal models based on this genetic information are now available and, importantly, patents disclosing common mechanisms are rapidly emerging among diseases that were once considered unrelated. The field is poised for the development of new therapies based on high throughput screenings and a better understanding of the molecular and cellular mechanisms leading to neurodegeneration.

POTENTIAL BIOLOGICAL THERAPIES

Key patents disclose drug discovery platforms using gene sequencing and proteomics to show the involvement of multiple cellular pathways in a given pathogenic process. A landmark in treating neurodegenerative diseases was clinically demonstrated recently by antisense oligonucleotides for Huntington’s Disease and Spinal Muscular Atrophy. Antisense oligonucleotides inactivate mRNA in the translation process and block protein production. In this groundbreaking treatment for Huntington’s , antisense oligonucleotides were designed to specifically target a mutation in the gene that codes for a toxic huntingtin protein. This toxic protein causes Huntington’s by aggregating in the brain and causing brain cells to die. In the clinical trial, antisense oligonucleotides reduced the amount of mutated toxic huntingtin protein. Since toxic proteins are implicated in all neurodegenerative disease, a race is on to identify new disease targets which will be attacked by antisense oligonucleotides.

Patent filings increased on over-expressed microRNAs (miRNAs, endogenous small RNAs binding the target sites of protein-coding genes, which lead to their degradation of translation) implicating their over-expression in several neurodegenerative processes. This implies that alterations in miRNA regulatory pathways suggest miRNAs represent a novel class of therapeutic targets in these diseases.. Considering the growing interest in the potential of miRNAs, it is also plausible that these findings may lead to develop miRNAs therapeutics also for NDDs.

Additional potential therapies include more effective antibodies to biological targets that cross the blood brain barrier, boosting the immune system with vaccines, and gene therapy technology to replace defective enzymes using an AAV vector that allows the enzymes entry into the brain.

CONCLUSION

Investing, marketing and patenting trends indicate better understanding of the mechanisms underlying neurodegeneration should lead to more effective, disease-modifying treatments in the future. In spite of the challenges, research and drug development in neuroscience and neurodegenerative diseases is pushing new frontiers. The prospect of real breakthroughs is on the horizon. Possibilities provided by the current progress in biotechnology innovation will yield by the year 2050 to new life-changing medicines for these devastating neurodegenerative diseases which are currently incurable.

The following Examiners were consulted regarding the field of search:

Examiner Chong in Art Unit 1674
Examiner Ketter in Art Unit 1636
Examiner Stucker in Art Unit 1649
Examiner Kim in Art Unit 1651

The following classes and subclasses were searched:

Class 424 (Drug, Bio-affecting And Body Treating Compositions)
   Subs. 130.1, 135.1, 141.1, 184.1
Class 435 (Chemistry: Molecular Biology And Microbiology)
   Subs. 328, 336
Class 514 (Drug, Bio-affecting And Body Treating Compositions)
   Subs. 44A
Class 530 (Chemistry: Natural Resins Or Derivatives; Peptides Or Proteins; Lignins Or Reaction Products Thereof)
   Subs. 388.1, 809

The following IPC-8 classes and subclasses were searched:

Class A61K (PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES)
31/713  Medicinal preparations containing organic active ingredients; Carbohydrates; Sugars; Derivatives thereof; Compounds having three or more nucleosides or nucleotides; Double-stranded nucleic acids or oligonucleotides
38/00  Medicinal preparations containing peptides
38/04  Medicinal preparations containing peptides; Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
38/08  Medicinal preparations containing peptides; Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof; Peptides having 5 to 11 amino acids
38/10  Medicinal preparations containing peptides; Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof; Peptides having 12 to 20 amino acids
38/17  Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; from animals; from humans
39/00  Medicinal preparations containing antigens or antibodies
39/395  Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Class A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS)
25/28  Drugs for disorders of the nervous system; for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimers disease or other forms of dementia s disease or other forms of dementia
Class C12N (MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF ; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA)
15/11  Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; DNA or RNA fragments; Modified forms thereof
15/113  Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Class G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES)
33/00  Investigating or analysing materials by specific methods not covered by groups G01N 1/00-G01N 31/00
33/15  Investigating or analysing materials by specific methods not covered by groups G01N 1/00-G01N 31/00; Medicinal preparations
33/68  Investigating or analysing materials by specific methods not covered by groups G01N 1/00-G01N 31/00; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing; involving proteins, peptides or amino acids
Class C12P (FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE)
21/06  Preparation of peptides or proteins; produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Class C07K (PEPTIDES)
14/47  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; from animals; from humans; from vertebrates; from mammals
16/00  Immunoglobulins, e.g. monoclonal or polyclonal antibodies
16/18  Immunoglobulins, e.g. monoclonal or polyclonal antibodies; against material from animals or humans
Class C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES)
1/68  Measuring or testing processes involving enzymes or micro-organisms ; Compositions therefor; Processes of preparing such compositions; involving nucleic acids

The following CPC classes and subclasses were searched:

Class A61K (PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES)
31/7105  Medicinal preparations containing organic active ingredients; Carbohydrates; Compounds having three or more nucleosides or nucleotides; Natural ribonucleic acids ie containing only riboses attached to adenine guanine cytosine or uracil and having 3&apos-5&apos phosphodiester links
31/713  Medicinal preparations containing organic active ingredients; Carbohydrates; Compounds having three or more nucleosides or nucleotides; Double-stranded nucleic acids or oligonucleotides
38/1709  Medicinal preparations containing peptides; Peptides having more than 20 amino acids; from animals; {from vertebrates }; {from mammals}
39/00  Medicinal preparations containing antigens or antibodies
39/0005  Medicinal preparations containing antigens or antibodies; {Vertebrate antigens }
39/0007  Medicinal preparations containing antigens or antibodies; {Vertebrate antigens }; {Nervous system antigens Prions}
39/12  Medicinal preparations containing antigens or antibodies; Viral antigens
39/39  Medicinal preparations containing antigens or antibodies; characterised by the immunostimulating additives eg chemical adjuvants
39/3955  Medicinal preparations containing antigens or antibodies; Antibodies; {against materials from animals}; {against proteinaceous materials eg enzymes hormones lymphokines}
2039/505  Medicinal preparations containing antigens or antibodies; {comprising antibodies}
2039/6075  Medicinal preparations containing antigens or antibodies; {characteristics by the carrier linked to the antigen}; {Proteins}; {Viral proteins}
48/00  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases
48/005  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; {characterised by an aspect of the &aposactive&apos part of the composition delivered ie the nucleic acid delivered}
Class C07K (PEPTIDES)
14/4711  Peptides having more than 20 amino acids; from animals; from vertebrates; from mammals; {not used}; {Alzheimer&aposs disease Amyloid plaque core protein}
16/18  Immunoglobulins [IGs] eg monoclonal or polyclonal antibodies; against material from animals or humans
16/40  Immunoglobulins [IGs] eg monoclonal or polyclonal antibodies; against enzymes
2317/569  Immunoglobulins specific features; characterized by immunoglobulin fragments; variable region ie VH andor VL; Single domain eg dAb sdAb VHH VNAR or nanobody&174
2317/622  Immunoglobulins specific features; characterized by non-natural combinations of immunoglobulin fragments; comprising only variable region components; Single chain antibody
2317/76  Immunoglobulins specific features; characterized by effect upon binding to a cell or to an antigen; Antagonist effect on antigen eg neutralization or inhibition of binding
Class C12N (MICROORGANISMS OR ENZYMES)
5/0619  Undifferentiated human animal or plant cells eg cell lines; {Animal cells or tissues Human cells or tissues Not used see subgroups}; {Vertebrate cells}; {Cells of the nervous system}; {Neurons}
5/0623  Undifferentiated human animal or plant cells eg cell lines; {Animal cells or tissues Human cells or tissues Not used see subgroups}; {Vertebrate cells}; {Cells of the nervous system}; {Stem cells}
15/113  Mutation or genetic engineering; Recombinant DNA-technology; DNA or RNA fragments; Non-coding nucleic acids modulating the expression of genes eg antisense oligonucleotides
15/1137  Mutation or genetic engineering; Recombinant DNA-technology; DNA or RNA fragments; Non-coding nucleic acids modulating the expression of genes eg antisense oligonucleotides; {against enzymes }
15/86  Mutation or genetic engineering; Recombinant DNA-technology; Introduction of foreign genetic material using vectors; Vectors or expression systems specially adapted for eukaryotic hosts; for animal cells; Viral vectors
2310/11  Structure or type of the nucleic acid; Type of nucleic acid; Antisense
2310/113  Structure or type of the nucleic acid; Type of nucleic acid; Antisense; targeting other non-coding nucleic acids eg antagomirs
2310/14  Structure or type of the nucleic acid; Type of nucleic acid; interfering NA
2310/141  Structure or type of the nucleic acid; Type of nucleic acid; interfering NA; MicroRNAs miRNAs
2510/00  Genetically modified cells
2730/10134  Reverse Transcribing DNA Viruses; Reverse Transcribing DNA Viruses; Hepadnaviridae; Orthohepadnavirus eg hepatitis B virus; Use of virus or viral component as vaccine eg live-attenuated or inactivated virus VLP viral protein
2760/18434  ssRNA Viruses negative-sense; ssRNA Viruses negative-sense; Paramyxoviridae; Morbillivirus eg Measles virus canine distemper; Use of virus or viral component as vaccine eg live-attenuated or inactivated virus VLP viral protein
Class C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS)
1/6883  Measuring or testing processes involving enzymes {nucleic acids} or microorganisms; involving nucleic acids; {Hybridisation probes}; {for diseases caused by alterations of genetic material}
2600/156  Oligonucleotides characterized by their use; Polymorphic or mutational markers
2600/158  Oligonucleotides characterized by their use; Expression markers
2600/178  Oligonucleotides characterized by their use; miRNA siRNA or ncRNA
Class C12Y (ENZYMES)
304/23046  Hydrolases acting on peptide bonds ie peptidases; Aspartic endopeptidases; Memapsin 2 ie beta-secretase 1 or BACE
Class G06F (ELECTRICAL DIGITAL DATA PROCESSING)
19/20  Digital computing or data processing equipment or methods specially adapted for specific applications; Bioinformatics ie methods or systems for genetic or protein-related data processing in computational molecular biology; for hybridisation or gene expression eg microarrays sequencing by hybridisation normalisation profiling noise correction models expression ratio estimation probe design or probe optimisation
Class G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES)
33/5058  Investigating or analysing materials by specific methods not covered by the preceding groups; Biological material eg blood urine; Chemical analysis of biological material eg blood urine; {involving human or animal cells }; {for testing or evaluating the effect of chemical or biological compounds eg drugs cosmetics}; {involving specific cell types}; {Neurological cells}
33/5073  Investigating or analysing materials by specific methods not covered by the preceding groups; Biological material eg blood urine; Chemical analysis of biological material eg blood urine; {involving human or animal cells }; {for testing or evaluating the effect of chemical or biological compounds eg drugs cosmetics}; {involving specific cell types}; {Stem cells}
33/573  Investigating or analysing materials by specific methods not covered by the preceding groups; Biological material eg blood urine; Chemical analysis of biological material eg blood urine; Immunoassay; for enzymes or isoenzymes
33/6896  Investigating or analysing materials by specific methods not covered by the preceding groups; Biological material eg blood urine; Chemical analysis of biological material eg blood urine; involving proteins peptides or amino acids; {related to diseases not provided for elsewhere}; {Neurological disorders eg Alzheimer&aposs disease}
2333/4709  Assays involving biological materials from specific organisms or of a specific nature; from animals; from vertebrates; Assays involving proteins of known structure or function as defined in the subgroups; ; Amyloid plaque core protein
2333/936  Assays involving biological materials from specific organisms or of a specific nature; Enzymes; Hydrolases; acting on glycosyl compounds; acting on beta-1 4 bonds between N-acetylmuramic acid and 2-acetyl-amino 2-deoxy-D-glucose eg lysozyme
2500/10  Screening for compounds of potential therapeutic value; involving cells
2800/28  Detection or diagnosis of diseases; Neurological disorders
2800/2814  Detection or diagnosis of diseases; Neurological disorders; Dementia
2800/2821  Detection or diagnosis of diseases; Neurological disorders; Dementia; Alzheimer
2800/2835  Detection or diagnosis of diseases; Neurological disorders; Movement disorders eg Parkinson Huntington Tourette
C12N 5/86 The subclass number was searched but it does not exist in the current CPC database version

The following U.S. references for 'Biotech Landscape' were cited in the search:

9,951,330 [Crary et al]
9,932,394 [Henderson et al]
9,926,559 [Bennett et al]
9,926,354 [Tan et al]
9,908,933 [Miles et al]
9,896,504 [Weihofen et al]
9,849,195 [Davidson]
9,845,352 [Novak et al]
9,840,710 [Hastings et al]
9,834,596 [Holtzman et al]
9,822,171 [Barghorn et al]
9,822,156 [Haque et al]
9,771,617 [Dezso et al]
9,750,769 [Hazel et al]
9,683,236 [Hung et al]
9,683,235 [Freier]
9,657,091 [Pfeifer et al]
9,605,041 [Greengard et al]
9,585,956 [Pfeifer et al]
9,580,493 [Weihofen et al]
9,527,909 [Hayashi et al]
9,517,256 [Eisenbach-schwartz et al]
9,485,972 [Kontsekova]
9,464,122 [Moe et al]
9,316,650 [Kehrel et al]
9,301,969 [Roh et al]
9,290,759 [Abeliovich et al]
9,283,271 [Montrasio et al]
9,265,788 [Liu et al]
9,265,786 [Fox]
9,146,244 [Pfeifer et al]
9,109,037 [Ambrosino et al]
9,102,752 [Wang]
9,102,717 [Huang et al]
9,044,459 [Perrin et al]
9,018,180 [Pinner et al]
8,987,222 [Aronin et al]
8,980,270 [Griswold-prenner et al]
8,865,411 [Gitler et al]
8,828,404 [Eisenbach-schwartz et al]
8,809,506 [Lannfelt et al]
8,759,029 [Julien et al]
8,715,643 [Nonaka et al]
8,663,987 [Kadouri et al]
8,613,923 [Pfeifer et al]
8,597,660 [Pant et al]
8,501,465 [Lindquist et al]
8,497,072 [Hillen et al]
8,435,514 [Perrin et al]
8,106,164 [Gellerfors et al]
8,067,161 [Ono et al]
7,977,314 [Cashman]
7,659,243 [Greenway et al]
7,618,793 [Muchowski et al]
7,575,876 [Zhang]
7,553,639 [Chilcote et al]

2018/0127758 [Bennett]
2018/0119145 [Kordasiewicz]
2018/0094267 [Heslin et al]
2018/0094259 [Miller et al]
2018/0073021 [Vijaya et al]
2018/0066254 [Covello et al]
2018/0057604 [Liu et al]
2018/0038875 [Oh et al]
2017/0368167 [Agadjanyan et al]
2017/0362339 [Liu et al]
2017/0355756 [Julien et al]
2017/0335324 [Albers et al]
2017/0328919 [Constantin]
2017/0305986 [Klipstein et al]
2017/0283829 [Lipton et al]
2017/0253930 [Hatchwell et al]
2017/0246200 [Hebert]
2017/0175113 [Bennett et al]
2017/0152307 [Wadia et al]
2017/0143686 [Choi et al]
2017/0028021 [Alvarez-saavedra]
2017/0010284 [Sierks et al]
2017/0007633 [Bonni et al]
2016/0297852 [Willbold]
2016/0265057 [Smith et al]
2016/0251619 [Karussis et al]
2016/0166663 [Marciani]
2016/0154011 [Lovestone]
2016/0082015 [Rubin]
2016/0068581 [Wang]
2015/0240222 [Shorter et al]
2014/0162933 [Hatchwell et al]
2013/0108645 [Farah]
2013/0065834 [Vilchez et al]
2007/0204352 [Caldwell et al]

The following foreign references for 'Biotech Landscape' were also noted of interest:

WO 2018085653A1 [Masliah et al]
WO 2018077303A1 [Chu et al]
WO 2018075373A1 [Francois]
WO 2018055577A1 [Renner et al]
WO 2018048877A1 [Mccown et al]
WO 2018045347A1 [High et al]
WO 2017207979A1 [Hautbergue et al]
WO 2017196432A1 [Ho et al]
WO 2017173234A1 [Maclennan]
WO 2017123065A1 [Lee et al]
WO 2017075729A1 [Hetz et al]
WO 2017059554A1 [Hetz et al]
WO 2017040271A1 [Passini et al]
WO 2016179497A1 [Park et al]
WO 2016088797A1 [Ishikawa et al]
WO 2015134551A1 [Prima et al]
WO 2015048100A1 [Agbas]
WO 2015016392A1 [Tsuji et al]
WO 2015004163A1 [De et al]
WO 2013166183A2 [Bogoch et al]
WO 2013134403A1 [Koval et al]
WO 2013122502A1 [Ataullakhanov et al]
WO 2013059322A2 [Steinman et al]
WO 2012061723A2 [Brunden et al]
WO 2011123388A1 [Gitler]
WO 2010129021A1 [Passini et al]
WO 2010008860A1 [Glimcher et al]
WO 2009117387A2 [Abeliovich et al]
WO 2007135426A2 [Wade-martins et al]
WO 2004041204A2 [Joazeiro et al]
WO 2011013034 [Smith et al]
WO 03090689A2 [Svendsen et al]
WO 9614399A1 [Isacson et al]
EP 3303589A1 [Jackson et al]
EP 2723866B1 [Julien et al]
EP 2646053A2 [Holtzman et al]
EP 2145628B1 [Kaemmerer et al]
EP 1701730B1 [Eisenbach-schwartz et al]
CN 106568969B [Yang et al]

These patents are representative of the references searched. Copies of the cited references are enclosed for your further review. For additional information on the cited references, please see the patent family, located on the CD results, for related patents and the legal status of cited patents. Please do not hesitate to contact me with any questions regarding this search.

Best Regards,
EXPRESS SEARCH

Cristopher H. Flagg
President
 

CHF
Enclosure: References for 'Biotech Landscape' – 130 Patents
Ref: E00-81617